Dr. Xingli Wang

So far, we have not seen.

We have tested quite a few different HER2 antibodies.

It hasn't been overlapping.

Again, when you develop the monoclonal sometimes, you don't do that by design because you don't really know when you design the monoclonal.

And often, by screening out, the ones you feel be standing out or unique of which epitope you're working on.

So...

Right.

Interesting biology.

We when I was in America, we called Kiskelly.

Yeah.

That's one of the interesting side of pharmaceutical companies, they always making the name which difficult struggling to pronounce.

I mean, currently we have over about 13 different indications we are working on.

We're almost like trying to make it, you know, anticipating as a fundamental therapies for most of solid tumor of the PD-L1 expressing solid tumor.

obviously you need to put tumors we anticipate to respond well as we currently observe the non-seminal cell lung cancer responded very well some of the cancers not responding well as we tested in in our phase two of the 13 different you know the solid tumors

is the ones we're anticipating or as also expected is the PD-L1 rich tumors.

And that would be the patients we will feel will get most benefit of.

And as a part of development strategy, we have a good drug like this.

We like full on, all in type of approach.

In our phase two, we just screen, almost like screening out.

Each group, you may have like 80 patients, 60 patients, depending on the prevalence, depending on severity, and to see how it goes.